Rimegepant for Sudden Attacks of Vestibular Migraine
Tests rimegepant against placebo for attacks of vestibular migraine in adults.
Plain-language title generated from the registry record
Registry title: Acute Treatment of Vestibular Migraine by Rimegepant
Key facts
- Where
- Wuhan, ChinaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07871097, who can take part
Where in China
- Tongji HospitalWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wensheng Qu
- Trial code
- NCT07871097
- Record updated
- 13 October 2026
- Original description
To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.Read full original descriptionShow less
Efficacy of Rimegepant in the Treatment of Acute Vestibular Migraine -- Multicenter, Prospective, Cross-design, Randomized, Placebo-controlled Study
To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.
Inclusion: Age 18-60 years, male or female; Diagnosis of vestibular migraine according to the Bárány Society criteria; ≥4 episodes of characteristic vestibular symptoms in the past year, each of moderate to severe intensity and lasting >2 hours (without intervention); Signed informed consent obtained from the participant.
Exclusion: Known pregnancy or lactation, or a positive pregnancy test prior to randomization; Initiation or dose adjustment of any preventive migraine therapy within 3 months prior to study drug administration; Use of any other anti-vertigo or analgesic medication within 6 hours before study drug administration; Presence of other disorders causing acute vestibular symptoms (e.g., Ménière's disease, otitis media); Coexisting non-vertiginous dizziness (e.g., dizziness due to panic disorder), unless the patient can clearly distinguish these episodes from vestibular-migraine attacks; Severe cardiovascular or cerebrovascular disease; Contraindication or hypersensitivity to any medications used in the study; Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study or poses significant risk; Severe hepatic dysfunction (ALT and/or AST >3× upper limit of normal) or renal impairment (creatinine clearance <30 mL/min); Alcohol abuse or substance abuse; Participation in another interventional clinical study that could affect outcome assessment.